1. Home
  2. GYRE vs TV Comparison

GYRE vs TV Comparison

Compare GYRE & TV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GYRE
  • TV
  • Stock Information
  • Founded
  • GYRE 2002
  • TV 1969
  • Country
  • GYRE United States
  • TV Mexico
  • Employees
  • GYRE N/A
  • TV N/A
  • Industry
  • GYRE Biotechnology: Pharmaceutical Preparations
  • TV Broadcasting
  • Sector
  • GYRE Health Care
  • TV Industrials
  • Exchange
  • GYRE Nasdaq
  • TV Nasdaq
  • Market Cap
  • GYRE 897.1M
  • TV 1.1B
  • IPO Year
  • GYRE N/A
  • TV 1993
  • Fundamental
  • Price
  • GYRE $7.42
  • TV $2.37
  • Analyst Decision
  • GYRE
  • TV Buy
  • Analyst Count
  • GYRE 0
  • TV 4
  • Target Price
  • GYRE N/A
  • TV $3.87
  • AVG Volume (30 Days)
  • GYRE 253.7K
  • TV 1.9M
  • Earning Date
  • GYRE 08-12-2025
  • TV 07-22-2025
  • Dividend Yield
  • GYRE N/A
  • TV 3.63%
  • EPS Growth
  • GYRE N/A
  • TV N/A
  • EPS
  • GYRE 0.02
  • TV N/A
  • Revenue
  • GYRE $100,643,000.00
  • TV $2,998,354,359.00
  • Revenue This Year
  • GYRE $21.04
  • TV N/A
  • Revenue Next Year
  • GYRE $89.64
  • TV N/A
  • P/E Ratio
  • GYRE $93.77
  • TV N/A
  • Revenue Growth
  • GYRE N/A
  • TV N/A
  • 52 Week Low
  • GYRE $6.11
  • TV $1.55
  • 52 Week High
  • GYRE $19.00
  • TV $2.78
  • Technical
  • Relative Strength Index (RSI)
  • GYRE 39.71
  • TV 68.17
  • Support Level
  • GYRE $7.26
  • TV $2.22
  • Resistance Level
  • GYRE $8.00
  • TV $2.23
  • Average True Range (ATR)
  • GYRE 0.49
  • TV 0.09
  • MACD
  • GYRE -0.07
  • TV 0.03
  • Stochastic Oscillator
  • GYRE 10.36
  • TV 80.19

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

About TV Grupo Televisa S.A.

Televisa is one of the leading telecommunication firms in Mexico. Its cable arm, Izzi, holds networks that pass 20 million Mexican homes and provide broadband service to nearly 6 million customers. The firm is also one of the largest pay-television providers in Mexico, with 4 million customers. Televisa owns Sky Mexico, the country's only satellite-TV provider, serving about 5 million customers. After merging its traditional media business into Univision, Grupo Televisa owns a 43% stake in combined entity TelevisaUnivision. Grupo Televisa spun off several smaller businesses, including magazine publishing, three of Mexico's professional soccer teams, and Azteca Stadium in February 2024, under the name Ollamani.

Share on Social Networks: